Novel tubulin-binding vascular disrupting agent (VDA)

Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp

Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor

Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8

Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL)

Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL)

Seletive dopamine D3 receptors

Novel highly potent and soluble partial FXR agonist

Novel histamine H3 receptor ligand

Antiviral agent against LASV and a number of other viruses in the Arenaviridae family

Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor

Novel histamine H3 receptor ligand

Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs

Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro

Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs

Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs

Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner

Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay

Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist

Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2)

Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly

Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity

Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway

Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro.

Elongation factor P (EF-P) fuction modifier

Novel antimalarial agent

The first selective inhibitor of Histone Deacetylase 2 (HDAC2)

Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin

Non-selective potent dopamine reuptake inhibitor